AGP Executive Report
Last update: 7 hours agoCancer Care in Europe: The EU’s CHMP has issued a positive opinion for perioperative KEYTRUDA (pembrolizumab) plus PADCEV (enfortumab vedotin) for resectable muscle-invasive bladder cancer, with a final European Commission decision expected in Q4 2026—potentially expanding use across EU states including Iceland. Short Bowel Treatment: Zealand Pharma also got a positive CHMP opinion for Zeydovio (glepaglutide) for adults with short bowel syndrome, reporting meaningful reductions in weekly parenteral support and some patients weaning off entirely. Eye Health: Lupin/VISUfarma secured EU commercialization rights for Yuvezzi, a once-daily eye drop aimed at temporary near-vision improvement for up to eight hours (not a permanent replacement for reading glasses). Mental Health & Movement: A Latvian man is walking around the world to support his mental health, saying a trip to Iceland helped him find happiness. Prepared Food & Wellness: Florette is launching a ready-to-eat “House Salad Bowl” in Iceland stores, positioning it as an easier, healthier lunch option. Air Quality Warning: IQAir’s report ranks Pakistan the most polluted country for PM2.5, underscoring ongoing respiratory health risks worldwide. Gender Equity Watch: New WEF findings show women’s progress into top management is stalling, with fewer women hired into senior roles since 2022.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
